DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Robert NJ, Diéras V, Glaspy J. et al.
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2–negative, locally recurrent or metastatic breast cancer.
J Clin Oncol 2011;
29: 1252-1260
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.